Sanofi News

6-K: Strong Q1 Performance and 2025 Guidance Confirmed

Apr 24 10:14 ET

SCHEDULE 13G/A: Others

Apr 23 19:40 ET

6-K: Dupixent Approved in the US as the First New Targeted Therapy in over a Decade for Chronic Spontaneous Urticaria

Apr 22 12:29 ET

6-K: Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Apr 16 09:18 ET

6-K: Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Apr 10 06:12 ET

6-K: Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Apr 4 08:44 ET

6-K: Dupixent Approved as the First-Ever Biologic Medicine in Japan for Patients with COPD and Qfitlia Approved as the First Therapy in the US to Treat Hemophilia A or B with or Without Inhibitors

Apr 2 06:16 ET

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 27 13:39 ET

6-K: Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis and Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Mar 26 11:57 ET

S-8 POS: S-8 POS

Mar 21 06:05 ET

6-K: Sanofi to Acquire Dren Bio's Bispecific Myeloid Cell Engager for Deep B-Cell Depletion, Broadening Immunology Pipeline

Mar 20 11:07 ET

6-K: Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Mar 10 12:23 ET

6-K: Sanofi Successfully Prices Eur 1.5 Billion of Bond Issue

Mar 6 10:25 ET

6-K: New Duvakitug Data Reinforce Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease and Sarclisa Approved in Japan for Patients with Newly Diagnosed Multiple Myeloma

Feb 28 06:15 ET

6-K: Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid and Sanofi and CD&R Sign Opella Share Purchase Agreement

Feb 20 12:22 ET

SCHEDULE 13G/A: Others

Feb 14 12:19 ET

13F-HR: Information required of institutional investment managers pursuant to Section 13(f)

Feb 14 11:30 ET

IRANNOTICE: IRANNOTICE

Feb 13 14:14 ET

20-F: FY2024 Annual Report

Feb 13 13:49 ET

6-K: Update on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

Feb 13 12:24 ET